implantable device
Back to the drawing board for Vertex’s ‘cells plus device’ diabetes programme
Vertex Pharmaceuticals, VX-264, type 1 diabetes, cell therapy, implantable device, clinical trial failure, zimislecel, insulin production
Actionable Insights Powered by AI
Vertex Pharmaceuticals, VX-264, type 1 diabetes, cell therapy, implantable device, clinical trial failure, zimislecel, insulin production